ReviewAmerican journal of therapeutics2012

Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.

James J Driscoll et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.